For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Dihydrocodeine tartrate - Pain
PAD Profile : Dihydrocodeine tartrate - Pain
Traffic Light Status
Status 1 of 2.
- Oral solution
- Tablets
Status 2 of 2.
- Modified release tablets
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Oxycodone
- Co-codamol (Codeine phosphate/paracetamol)
- Tramadol hydrochloride
- Oxycodone hydrochloride/naloxone hydrochloride
- Fentanyl
- Tramadol hydrochloride
- Tramadol hydrochloride
- Paracetamol
- Codeine phosphate
- Buprenorphine
- Morphine sulfate
- Pregabalin
- Gabapentin
- Dronabinol/cannabidiol
- Co-dydramol (Dihydrocodeine/paracetamol)
- Ibuprofen
- Meptazinol hydrochloride
- Pethidine hydrochloride
- Diamorphine hydrochloride
- Alfentanil hydrochloride
- Co-dydramol (Dihydrocodeine/paracetamol)
- Co-dydramol (Dihydrocodeine/paracetamol)
- Nefopam hydrochloride
- Papaveretum
- Aspirin
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
Persistent Non-Malignant Pain Guidelines
A stepped approach to pain management is recommended. Paracetamol is considered a 1st line option for the treatment of persistent non-malignant pain. A trial of codeine should be initiated where a weak opioid is indicated. Please see narrative below regarding specific products. Refer to specific pages on PAD for products containing codeine phosphate (including combination products) and refer to persistent non-maligant pain guidelines attached:
- Dihydrocodeine (standard release) 30mg tablets - GREEN
- Dihydrocodeine oral solution - GREEN (treatment option if oral solution is indicated)
- Dihydrocodeine sustained release tablets - GREEN (use if standard release tablets are not tolerated or compliance is an issue. Initiate at a low dose).
Consider a patient agreement is completed by the patient (see below) prior to a trial of Dihydrocodeine